Drug-Induced Hypouricemia
- PMID: 39289314
- DOI: 10.1007/s40264-024-01485-7
Drug-Induced Hypouricemia
Abstract
Hypouricemia is defined as a serum uric acid concentration of ≤ 2.0 mg/dL or 119 μmol/L. Hypouricemia may occur secondarily to a number of underlying conditions, including severe hepatocellular disease, neoplasia, defective renal tubular reabsorption of uric acid, inherited metabolic defect in purine metabolism, and drugs. Medications are an important cause of hypouricemia. They can cause hypouricemia by a variety of mechanisms. Drug-induced hypouricemia mostly occurs as overtreatment of hyperuricemia by urate-lowering therapies including xanthine oxidase inhibitors, uricosuric agents and uricases. Drugs not used in the treatment of gout may also lead to a decrease of uric acid levels. In this literature review, medications leading to hypouricemia are summarized with regard to their mechanism of action and clinical significance.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Funding: No funding. Conflict of interest: Authors have no conflicts of interest that are directly relevant to the content of this article. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable. Availability of data and material: Upon reasonable request, data will be shared with qualified scientifc and medical researchers. All requests should be submitted in writing to the corresponding author. Code availability: Not applicable. Author contributions: CBS and MA performed the literature review and wrote the first draft of the manuscript. All authors made significant contribution to the writing, development, and editing of this manuscript. All authors read and approved the final version.
Similar articles
-
Potential Dangers of Serum Urate-Lowering Therapy.Am J Med. 2019 Apr;132(4):457-467. doi: 10.1016/j.amjmed.2018.12.010. Epub 2019 Jan 3. Am J Med. 2019. PMID: 30611833 Review.
-
Patients with gout differ from healthy subjects in renal response to changes in serum uric acid.Joint Bone Spine. 2017 Mar;84(2):183-188. doi: 10.1016/j.jbspin.2016.04.007. Epub 2016 Jun 17. Joint Bone Spine. 2017. PMID: 27324603 Clinical Trial.
-
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Clin Ther. 2009. PMID: 20109996 Review.
-
Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.Phytomedicine. 2023 Sep;118:154957. doi: 10.1016/j.phymed.2023.154957. Epub 2023 Jul 11. Phytomedicine. 2023. PMID: 37478683
-
Approach to the treatment of hyperuricemia.Med Health R I. 2009 Nov;92(11):359-62. Med Health R I. 2009. PMID: 19999894 Review. No abstract available.
References
-
- Praetorius E, Kirk JE. Hypouricemia: with evidence for tubular elimination of uric acid. J Lab Clin Med. 1950;35:865–8. - PubMed
-
- Ogino K, Hisatome I, Saitoh M, Miyamoto J, Ishiko R, Hasegawa J, et al. Clinical significance of hypouricemia in hospitalized patients. J Med. 1991;22:76–82. - PubMed
-
- Iwai N, Mino Y, Hosoyamada M, Tago N, Kokubo Y, Endou H. A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int. 2004;66:935–44. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical